Dattatreya S Banavara

8287931, Oct 16, 2012

May 11, 2009

12/463981

Francisco J. Rosales - Singapore, SG
Eric van Tol - Arnhem, NL
Gyan P. Rai - Newburgh IN, US
Kristin Morris - Evansville IN, US
Dattatreya Banavara - Newburgh IN, US
Dirk Hondmann - Newburgh IN, US
Zeina E. Jouni - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Deborah A. Schade - Evansville IN, US
Donald Carey Walker - Evansville IN, US

Mead Johnson Nutrition Company - Evansville IN

A23L 1/30

426 72

A nutritional composition for improving the immunological function of a subject, including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and about 0. 1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which has a fermentation rate which is demonstrably slower than that of galacto-oligosaccharide.

8287932, Oct 16, 2012

May 11, 2009

12/463994

Francisco J. Rosales - Singapore, SG
Gyan P. Rai - Newburgh IN, US
Kristin Morris - Evansville IN, US
Dattatreya Banavara - Newburgh IN, US
Dirk Hondmann - Newburgh IN, US
Eric van Tol - MZ Arnhem, NL
Zeina E. Joani - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Deborah A. Schade - Evansville IN, US
Donald Carey Walker - Evansville IN, US

Mead Johnson Nutrition Company - Evansville IN

A23L 1/30

426 72

A nutritional composition including a lipid or fat; a protein source; at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and at least about 0. 2 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises a plurality of oligosaccharides such that the overall fermentation rate profile of the prebiotic composition provides an increased population of beneficial bacteria in the human gut over an extended period of time.

8293264, Oct 23, 2012

May 11, 2009

12/463968

Francisco J. Rosales - Singapore, SG
Eric van Tol - Evansville IN, US
Gyan P. Rai - Newburgh IN, US
Dirk Hondmann - Newburgh IN, US
Kristin Morris - Evansville IN, US
Dattatreya Banavara - Newburgh IN, US
Zeina E. Jouni - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Deborah A. Schade - Evansville IN, US
Donald Carey Walker - Evansville IN, US

Mead Johnson Nutrition Company - Evansville IN

A23C 9/12
A23C 17/00
A23J 1/00
A23L 1/30
A61K 47/00
A01N 63/00
C12N 1/20

424439, 424 934, 426 43, 426 72, 426601, 426656, 426801, 4352529, 435853

A nutritional formula which includes a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0. 1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which comprises galacto-oligosaccharide; and about 0. 015 to about 0. 1 (pg/μg) ppm of TGF-β.

8648036, Feb 11, 2014

Dec 29, 2010

12/980813

Anja Wittke - Evansville IN, US
Dattatreya Banavara - Evansville IN, US
Cecilia Munoz - Evansville IN, US

Mead Johnson Nutrition Company - Glenview IL

A61K 38/40
A61K 31/715
A01N 63/00

514 25, 514 54, 424 9345

A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source.

20100104545, Apr 29, 2010

May 11, 2009

12/464029

Francisco J. Rosales - Singapore, SG
Gyan P. Rai - Newburgh IN, US
Kristin Morris - Evansville IN, US
Dattatreya Banavara - Newburgh IN, US
Eric van Tol - Evansville IN, US
Zeina E. Jouni - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Deborah A. Schade - Evansville IN, US
Donald Carey Walker - Evansville IN, US

A61K 45/00
A23L 1/30
A23L 1/09
A23C 9/13
A23C 9/123
A61K 38/00
A61P 1/00

424 9345, 426 74, 426 71, 426 61, 426648, 514 12, 424 934

A nutritional composition having a lipid or fat; a protein source; a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and up to about 2.5% by weight of a source of supplemental calcium which, when dissociated, provides a cation having prebiotic functionality.

20100104696, Apr 29, 2010

Feb 13, 2009

12/371100

Dattatreya Banavara - Newburgh IN, US
Deborah A. Schade - Evansville IN, US
Joaquin A. Franco - Newburgh IN, US
Juan M. Gonzalez - Newburgh IN, US
Dirk Hondmann - Newburgh IN, US
Zeina E. Jouni - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Kristin Morris - Evansville IN, US
Deshanie Rai - Newburgh IN, US
Gyan P. Rai - Newburgh IN, US
Nagendra Rangavajla - Dublin OH, US
Francisco J. Rosales - Newburgh IN, US
William Michael Russell - Newburgh IN, US
Eric Van Tol - Arnhem, NL
Hugh N. Tucker - Evansville IN, US
Donald Carey Walker - Evansville IN, US

Mead Johnson & Co. - Evansville IN

A23L 1/30
G06Q 30/00

426 72

The present invention is directed an improved nutritional composition, methods of improving digestion, and methods of enhancing the bioavailability of TGF-β.

20100104727, Apr 29, 2010

Feb 12, 2009

12/370374

Juan M. Gonzalez - Newburgh IN, US
Dattatreya Banavara - Newburgh IN, US
John A. Alvey - Evansville IN, US

Mead Johnson & Co. - Evansville IN

A23C 9/00

426588, 426580

The present invention is directed to a processing method and a selection of ingredients that will retain TGF-β levels, bioactivity, and/or bioavailability in a liquid nutritional product.

20120171163, Jul 5, 2012

Dec 29, 2010

12/980808

Anja Wittke - Evansville IN, US
Dattatreya Banavara - Evansville IN, US
Robert J. McMahon - Evansville IN, US
Cecilia Munoz - Evansville IN, US

A61K 35/74
A61K 38/40
A61P 31/04

424 934, 424 9345, 514 25

A method for inhibiting a bacterial invasive mechanism involving administering to a human a nutritional composition including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide; at least about 10 mg/100 kCal of lactoferrin selected from the group consisting of non-human lactoferrin, human lactoferrin produced by a genetically modified organism, and combinations thereof.